One of the biggest challenges in oncology is treatment resistance, which leads to poor prognosis when available therapies fail to halt cancer progression. Scientists are actively investigating the underlying mechanisms to develop strategies that can overcome acquired resistance across various cancer types.
Treatment resistance can be intrinsic, present from the start, or acquired over time as tumors adapt to therapy. Key mechanisms include genetic mutations, activation of alternative signaling pathways, enhanced DNA repair, drug efflux, and changes in the tumor microenvironment. Understanding these processes is critical for designing more effective treatments.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is among the companies developing innovative approaches. Their oncolytic virus therapies are designed to selectively infect and destroy cancer cells while stimulating an immune response. By equipping the immune system to recognize and attack tumors, these therapies may help circumvent resistance mechanisms. Oncolytic viruses can also be engineered to express immune-stimulating factors, potentially turning 'cold' tumors into 'hot' ones that respond better to immunotherapy.
Other research focuses on combination therapies that target multiple resistance pathways simultaneously. For instance, pairing targeted therapies with immunotherapy or using drug conjugates that deliver toxins directly to cancer cells. Biomarker identification is also crucial to predict which patients are likely to develop resistance and tailor treatments accordingly.
Despite these efforts, challenges remain. Tumors are heterogeneous, and resistance can emerge through multiple redundant pathways. Clinical trials are ongoing to evaluate the safety and efficacy of novel agents, including oncolytic viruses, in resistant cancers. The ultimate goal is to improve outcomes for patients who currently have limited options.
The fight against treatment resistance requires continued collaboration between academia, industry, and regulatory bodies. As research progresses, new insights into tumor biology and immune evasion will pave the way for more durable responses. For more information on oncolytic virus therapies, visit BioMedWire.
